EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

National Prescribing Trends and Cost Analysis of Antidepressants, Anxiolytics, and Hypnotics in England, 2010–2023

Mike Stedman, Mark Davies, John Warner- Levy, Joseph Ingram, David Taylor, Adrian Heald iD

Human Psychopharmacology: Clinical and Experimental · 2025-09 · 40 (5)

DOI: 10.1002/hup.70011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Psychopharmacology: Clinical and Experimental, online erschienen am 18.08.2025. Verfasst von Mike Stedman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Res Consortium, Andover, UK. Hauptthemen laut MEDLINE: Antidepressive Agents, COVID-19, Anti-Anxiety Agents, Hypnotics and Sedatives. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

We describe prescribing of anxiolytics/hypnotics/antidepressants at an all‐England level between 2010 and 2023, taking account of the influence of the COVID‐19 pandemic‐period.

Methods

All Primary Care Prescribing data for England for anxiolytics/hypnotics/antidepressant agents taken as tablets or capsules from 1 January 2010 to 31 December 2023 were considered.

Results

Antidepressants: the greatest increases were in sertraline prescriptions increasing from 2.9million 2010 by 685% to 23.0 million‐2023; duloxetine increased by 545% to 3.9million prescriptions; mirtazapine by 269% to 12.4million prescriptions. Regarding cost, overall average cost fell 2010‐2023 by 54% from £4.86(Euros 5.68) to £2.25(Euros 2.63) per prescription. Anxiolytics: the number of prescriptions for anxiolytics fell 6.5–4.8 m (−27%) overall, with all anxiolytics falling except buspirone. The greatest period of fall was seen between 2018 and 2023. Lorazepam/diazepam/chlordiazepoxide were down 23%,16%, 88% respectively. Average cost of prescriptions fell by 13% to £3.20(Euros 3.74). Hypnotics: the number of prescriptions for hypnotics fell 41% from 9.8million to 5.8million in 2023. All prescriptions fell in number. Annual trends showed no deviations for the COVID‐19 core pandemic (2020/2021) years.

Conclusion

Overall trends demonstrate a more than doubling of antidepressant prescribing over the period 2010–2023, with similar volume reduction in anxiolytics/hypnotics over the same period. Such real world data facilitate the development of policy influencing insights for psychotropic prescribing management now and in coming years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antidepressive AgentsCOVID-19Anti-Anxiety AgentsHypnotics and SedativesPractice Patterns, Physicians'Drug CostsDrug PrescriptionsHumansEnglandCosts and Cost Analysis

Stichwörter der Autor:innen

antidepressantanxiolyticgeneral practicehypnoticprescribingtrends

Substanzen

Antidepressive AgentsAnti-Anxiety AgentsHypnotics and Sedatives

Autor:innen und Institutionen

  • Res Consortium, Andover, UK.
  • University of Manchester, Manchester, UK.
  • Greater Manchester Mental Health, Manchester, UK.
  • Institute of Psychiatry, London, UK.
  • Department of Endocrinology, Salford Royal Hospital, Salford, UK.

ORCID-Profile: Adrian Heald

Zitieren

APA

Stedman, M., Davies, M., Levy, J. W., Ingram, J., Taylor, D., & Heald, A. (2025). National Prescribing Trends and Cost Analysis of Antidepressants, Anxiolytics, and Hypnotics in England, 2010–2023. Human Psychopharmacology: Clinical and Experimental, 40(5). https://doi.org/10.1002/hup.70011

Vancouver

Stedman M, Davies M, Levy JW, Ingram J, Taylor D, Heald A. National Prescribing Trends and Cost Analysis of Antidepressants, Anxiolytics, and Hypnotics in England, 2010–2023. Human Psychopharmacology: Clinical and Experimental. 2025;40(5). doi:10.1002/hup.70011

BibTeX
@article{Stedman2025,
  author = {Stedman, Mike and Davies, Mark and Levy, John Warner- and Ingram, Joseph and Taylor, David and Heald, Adrian},
  title = {National Prescribing Trends and Cost Analysis of Antidepressants, Anxiolytics, and Hypnotics in England, 2010–2023},
  journal = {Human Psychopharmacology: Clinical and Experimental},
  year = {2025},
  volume = {40},
  number = {5},
  doi = {10.1002/hup.70011}
}
Kostenlos starten →